IN191496B - - Google Patents

Info

Publication number
IN191496B
IN191496B IN1036DE1999A IN191496B IN 191496 B IN191496 B IN 191496B IN 1036DE1999 A IN1036DE1999 A IN 1036DE1999A IN 191496 B IN191496 B IN 191496B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Yatendra Kumar
Rakesh Kumar Arora
Kaptan Singh
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN1036DE1999 priority Critical patent/IN191496B/en
Priority to PCT/IB2000/001024 priority patent/WO2001009143A1/en
Priority to CN00812246A priority patent/CN1371381A/zh
Priority to JP2001513950A priority patent/JP2003506329A/ja
Priority to US10/048,354 priority patent/US6602999B1/en
Priority to BR0012865-1A priority patent/BR0012865A/pt
Priority to EP00944159A priority patent/EP1204667A4/en
Priority to AU58391/00A priority patent/AU5839100A/en
Priority to ZA200200692A priority patent/ZA200200692B/en
Publication of IN191496B publication Critical patent/IN191496B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1036DE1999 1999-07-30 1999-07-30 IN191496B (enExample)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IN1036DE1999 IN191496B (enExample) 1999-07-30 1999-07-30
PCT/IB2000/001024 WO2001009143A1 (en) 1999-07-30 2000-07-24 An improved amorphous form of cefpodoxime proxetil
CN00812246A CN1371381A (zh) 1999-07-30 2000-07-24 改进的无定形头孢泊肟酯
JP2001513950A JP2003506329A (ja) 1999-07-30 2000-07-24 セフポドキシメプロキセチルの改良アモルファス形態
US10/048,354 US6602999B1 (en) 1999-07-30 2000-07-24 Amorphous form of cefpodoxime proxetil
BR0012865-1A BR0012865A (pt) 1999-07-30 2000-07-24 Uma forma amorfa aperfeiçoada da proxetil cefpodoxima
EP00944159A EP1204667A4 (en) 1999-07-30 2000-07-24 AN IMPROVED AMORPHE FORM OF CEFPODOXIM PROXETIL
AU58391/00A AU5839100A (en) 1999-07-30 2000-07-24 An improved amorphous form of cefpodoxime proxetil
ZA200200692A ZA200200692B (en) 1999-07-30 2002-01-25 An improved amorphous form of cefpodoxime proxetil.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1036DE1999 IN191496B (enExample) 1999-07-30 1999-07-30

Publications (1)

Publication Number Publication Date
IN191496B true IN191496B (enExample) 2003-12-06

Family

ID=11092065

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1036DE1999 IN191496B (enExample) 1999-07-30 1999-07-30

Country Status (9)

Country Link
US (1) US6602999B1 (enExample)
EP (1) EP1204667A4 (enExample)
JP (1) JP2003506329A (enExample)
CN (1) CN1371381A (enExample)
AU (1) AU5839100A (enExample)
BR (1) BR0012865A (enExample)
IN (1) IN191496B (enExample)
WO (1) WO2001009143A1 (enExample)
ZA (1) ZA200200692B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT408226B (de) * 1999-05-05 2001-09-25 Biochemie Gmbh Kristalliner 7-(2-(2-formylaminothiazol-4-yl)-2
WO2002068429A1 (en) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Process for the preparation of cefpodoxime proxetil
KR20090033405A (ko) * 2004-10-18 2009-04-02 테바 파마슈티컬 인더스트리즈 리미티드 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에 아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를 제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는 방법
MX2007014363A (es) * 2005-05-16 2009-04-15 Elan Pharma Int Ltd Composiciones de liberacion controlada y en forma de nanoparticulas que comprenden una cefalosporina.
KR100840132B1 (ko) * 2007-04-17 2008-06-23 재단법인서울대학교산학협력재단 포화 액체 이산화탄소를 사용한 세포독심 프록세틸의 건조
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
KR20150053963A (ko) * 2012-09-11 2015-05-19 닥터 레디스 레보러터리즈 리미티드 엔잘루타마이드 다형태 및 그의 제조
FI3265102T3 (fi) 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
WO2017046756A1 (en) * 2015-09-18 2017-03-23 Lupin Limited Proxetil and axetil esters of cefixime
SG11201809984PA (en) * 2016-05-09 2018-12-28 Anacor Pharmaceuticals Inc Crystal forms of crisaborole in free form and preparation method and use thereof
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CN109311905A (zh) * 2016-06-16 2019-02-05 泽农医药公司 螺-吲哚酮化合物的固态形式
JP2019526637A (ja) * 2016-09-06 2019-09-19 インデナ・ソチエタ・ペル・アチオニ 固体形態のインゲノール ３−（３，５−ジエチルイソオキサゾール−４−カルボキシラート）及びその調製方法
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
CN115477679A (zh) * 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
DK3601265T3 (da) * 2017-03-30 2023-09-18 Merck Patent Gmbh Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
KR102682430B1 (ko) 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
BR112020020246A8 (pt) * 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
CN110251467A (zh) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 一种无定形态头孢妥仑匹酯组合物的制备方法
CN110437259B (zh) * 2019-08-14 2021-12-07 中国药科大学 头孢泊肟酯柚皮素共无定形物及其制备方法
US20220380348A1 (en) * 2019-10-04 2022-12-01 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022164941A1 (en) 2021-01-26 2022-08-04 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
AU2022291927A1 (en) 2021-06-17 2024-01-04 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy
CN119256126A (zh) 2022-05-23 2025-01-03 国立大学法人名古屋工业大学 用湿式纺丝法连续制造包含无机填料粒子的生物降解性纤维材料的方法、以及用该方法制造的棉絮状的骨再生材料
EP4455897A1 (en) 2023-04-26 2024-10-30 NXP USA, Inc. A hub device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223153A (en) 1979-02-09 1980-09-16 Eli Lilly And Company Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea
IT1165253B (it) 1979-07-12 1987-04-22 Blasinachim Spa Procedimento di fabbricazione di acido chenodesossicolico cristallino puro
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
PT531875E (pt) * 1991-09-07 2004-08-31 Aventis Pharma Gmbh Diastereomeros do ester 1-(isopropoxicarboniloxi)-etilico do acido 3-cefem-4-carboxilico e processo para a sua preparacao
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
AT413383B (de) * 1998-01-09 2006-02-15 Sandoz Ag Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
US6602999B1 (en) 2003-08-05
JP2003506329A (ja) 2003-02-18
ZA200200692B (en) 2003-05-28
WO2001009143A1 (en) 2001-02-08
EP1204667A1 (en) 2002-05-15
BR0012865A (pt) 2002-07-09
AU5839100A (en) 2001-02-19
EP1204667A4 (en) 2002-10-30
CN1371381A (zh) 2002-09-25

Similar Documents

Publication Publication Date Title
BE2018C020I2 (enExample)
BE2015C057I2 (enExample)
BE2016C007I2 (enExample)
BE2015C018I2 (enExample)
BE2013C051I2 (enExample)
BE2013C020I2 (enExample)
BE2012C036I2 (enExample)
BE1025464I2 (enExample)
BE2008C046I2 (enExample)
JP2002507757A5 (enExample)
JP2002521141A5 (enExample)
BE2008C047I2 (enExample)
BE2011C004I2 (enExample)
BRPI0001672A2 (enExample)
BRPI0001542A2 (enExample)
JP2002525223A5 (enExample)
JP2002528905A5 (enExample)
BRPI0012675B8 (enExample)
BRPI0017522A2 (enExample)
JP2002526310A5 (enExample)
IN187487B (enExample)
BRMU7902607U2 (enExample)
BRPI0303609A (enExample)
IN186577B (enExample)
AU2000262176A8 (enExample)